Tg Therapeutics (TGTX) EBT (2011 - 2026)

Tg Therapeutics' EBT history runs 16 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• In Q1 2026, EBT rose 272.4% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $122.6 million (up 187.77% YoY), while the FY2025 annual figure was $107.7 million, up 307.02% from the prior year.
• EBT was $20.4 million for Q1 2026 at Tg Therapeutics, down from $45.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $113.9 million in Q3 2023 to a low of -$80.4 million in Q4 2022.
• Historically, EBT has averaged -$4.4 million across 5 years, with a median of $4.3 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBT plunged 96.25% in 2024, then surged 507.05% in 2025.
• A 5-year view of EBT shows it stood at -$80.4 million in 2022, then soared by 65.66% to -$27.6 million in 2023, then jumped by 195.36% to $26.3 million in 2024, then surged by 72.59% to $45.4 million in 2025, then sank by 55.19% to $20.4 million in 2026.
• The last three EBT figures came in at $20.4 million (Q1 2026), $45.4 million (Q4 2025), and $25.9 million (Q3 2025), per Business Quant data.